Suo-wen Xu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5023441/publications.pdf

Version: 2024-02-01

156	8,270	41344	64796
papers	citations	49 h-index	79 g-index

160	160	160	10125
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Harnessing polyphenol power by targeting eNOS for vascular diseases. Critical Reviews in Food Science and Nutrition, 2023, 63, 2093-2118.	10.3	10
2	Anxa1 in smooth muscle cells protects against acute aortic dissection. Cardiovascular Research, 2022, 118, 1564-1582.	3.8	19
3	PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective. Current Medicinal Chemistry, 2022, 29, 980-999.	2.4	9
4	The cross-talk between PARylation and SUMOylation in C/EBPÎ² at K134 site participates in pathological cardiac hypertrophy. International Journal of Biological Sciences, 2022, 18, 783-799.	6.4	4
5	Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE-/- mice. Pharmacological Research, 2022, 175, 106043.	7.1	8
6	Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacologica Sinica, 2022, 43, 2173-2190.	6.1	42
7	Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International Journal of Biological Sciences, 2022, 18, 2146-2162.	6.4	21
8	Resveratrol in Treating Diabetes and Its Cardiovascular Complications: A Review of Its Mechanisms of Action. Antioxidants, 2022, 11, 1085.	5.1	37
9	Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	53
10	Marijuana and endothelial dysfunction: new mechanism and therapy. Trends in Molecular Medicine, 2022, 28, 613-615.	6.7	3
11	A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db/db mice. Biochemical and Biophysical Research Communications, 2022, 622, 163-169.	2.1	4
12	Cardiovascular protective effect of black pepper (Piper nigrum L.) and its major bioactive constituent piperine. Trends in Food Science and Technology, 2021, 117, 34-45.	15.1	18
13	Targeting epigenetics in cancer: therapeutic potential of flavonoids. Critical Reviews in Food Science and Nutrition, 2021, 61, 1616-1639.	10.3	38
14	Emodin in atherosclerosis prevention: Pharmacological actions and therapeutic potential. European Journal of Pharmacology, 2021, 890, 173617.	3.5	21
15	The role of potassium in atherosclerosis. European Journal of Clinical Investigation, 2021, 51, e13454.	3.4	9
16	Autophagy and cardiac diseases: Therapeutic potential of natural products. Medicinal Research Reviews, 2021, 41, 314-341.	10.5	68
17	GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. International Journal of Biological Sciences, 2021, 17, 2050-2068.	6.4	75
18	Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics, 2021, 11, 4502-4515.	10.0	61

#	Article	IF	Citations
19	Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). Phytotherapy Research, 2021, 35, 3649-3664.	5.8	12
20	Medicinal plants and bioactive natural products as inhibitors of <scp>NLRP3</scp> inflammasome. Phytotherapy Research, 2021, 35, 4804-4833.	5.8	24
21	Curcumin Inhibits Lysophosphatidic Acid Mediated MCP-1 Expression via Blocking ROCK Signalling. Molecules, 2021, 26, 2320.	3.8	13
22	Sorting nexin 3 induces heart failure via promoting retromer-dependent nuclear trafficking of STAT3. Cell Death and Differentiation, 2021, 28, 2871-2887.	11.2	14
23	Targeting angiopoietinâ€like 3 in atherosclerosis: From bench to bedside. Diabetes, Obesity and Metabolism, 2021, 23, 2020-2034.	4.4	10
24	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological Reviews, 2021, 73, 924-967.	16.0	359
25	Metformin, Macrophage Dysfunction and Atherosclerosis. Frontiers in Immunology, 2021, 12, 682853.	4.8	59
26	Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship. Biomedicines, 2021, 9, 699.	3.2	37
27	Curcumin as a Natural Remedy for Atherosclerosis: A Pharmacological Review. Molecules, 2021, 26, 4036.	3.8	42
28	Back Cover Image. Phytotherapy Research, 2021, 35, ii.	5.8	0
29	A bibliometric study of COVID-19 research in Web of Science. Pharmacological Research, 2021, 169, 105664.	7.1	10
30	The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. Signal Transduction and Targeted Therapy, 2021, 6, 266.	17.1	33
31	Resveratrol and endothelial function: A literature review. Pharmacological Research, 2021, 170, 105725.	7.1	83
32	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators of Inflammation, 2021, 2021, 1-12.	3.0	11
33	Tolerogenic vehicles of antigens in the antigen-specific immunotherapy for autoimmunity. Journal of Drug Delivery Science and Technology, 2021, 65, 102772.	3.0	1
34	Natural products: The role and mechanism in lowâ€density lipoprotein oxidation and atherosclerosis. Phytotherapy Research, 2021, 35, 2945-2967.	5.8	43
35	Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics, 2021, 11, 9376-9396.	10.0	32
36	The association of elevated serum lipocalin 2 levels with diabetic peripheral neuropathy in type 2 diabetes. Endocrine Connections, 2021, 10, 1403-1409.	1.9	3

#	Article	IF	Citations
37	Natural AMPK Activators in Cardiovascular Disease Prevention. Frontiers in Pharmacology, 2021, 12, 738420.	3.5	8
38	Editorial: Epigenetic Regulation in Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 831851.	2.4	0
39	Natural Products and Cardiovascular Diseases. Current Molecular Pharmacology, 2021, 14, 923-924.	1.5	0
40	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	4.0	12
41	Flavonoid biosynthetic pathways in plants: Versatile targets for metabolic engineering. Biotechnology Advances, 2020, 38, 107316.	11.7	307
42	Curcumin, the golden spice in treating cardiovascular diseases. Biotechnology Advances, 2020, 38, 107343.	11.7	207
43	ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Progress in Lipid Research, 2020, 77, 101006.	11.6	118
44	Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-Î² signalling. Cellular and Molecular Life Sciences, 2020, 77, 243-251.	5.4	34
45	ROS directly activates transforming growth factor Î² type 1 receptor signalling in human vascular smooth muscle cells. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129463.	2.4	18
46	Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway. Pharmacological Research, 2020, 152, 104626.	7.1	77
47	Medicinal plants and bioactive natural compounds as inhibitors of <scp>HMGâ€CoA</scp> reductase: A literature review. BioFactors, 2020, 46, 906-926.	5.4	30
48	The Effect of Salvianolic Acid on Vascular Protection and Possible Mechanisms. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-9.	4.0	47
49	Traditional Chinese medicine in cardiovascular drug discovery. Pharmacological Research, 2020, 160, 105168.	7.1	22
50	Naringenin and naringin in cardiovascular disease prevention: A preclinical review. European Journal of Pharmacology, 2020, 887, 173535.	3.5	103
51	Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review. Frontiers in Cell and Developmental Biology, 2020, 8, 581015.	3.7	29
52	CD36 in Atherosclerosis: Pathophysiological Mechanisms and Therapeutic Implications. Current Atherosclerosis Reports, 2020, 22, 59.	4.8	61
53	Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2020, 532, 239-243.	2.1	2
54	Statins: Epidrugs with effects on endothelial health?. European Journal of Clinical Investigation, 2020, 50, e13388.	3.4	17

#	Article	IF	Citations
55	Editorial: Biomechanics in Translation: From Vascular Biology to Cardiovascular Drug Discovery. Frontiers in Bioengineering and Biotechnology, 2020, 8, 902.	4.1	0
56	COVID-19 and Kawasaki disease in children. Pharmacological Research, 2020, 159, 104951.	7.1	75
57	Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function. Frontiers in Pharmacology, 2020, 11, 635.	3.5	36
58	Toll-like Receptor 4 Stimulates Gene Expression via Smad2 Linker Region Phosphorylation in Vascular Smooth Muscle Cells. ACS Pharmacology and Translational Science, 2020, 3, 524-534.	4.9	12
59	Familial Hypercholesterolemia and Atherosclerosis: Animal Models and Therapeutic Advances. Trends in Endocrinology and Metabolism, 2020, 31, 331-333.	7.1	10
60	Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis. Pharmacological Research, 2020, 155, 104737.	7.1	26
61	Cyclodextrins: Potential therapeutics against atherosclerosis. , 2020, 214, 107620.		40
62	Targeting inflammation and cytokine storm in COVID-19. Pharmacological Research, 2020, 159, 105051.	7.1	79
63	Endothelial-specific YY1 governs sprouting angiogenesis through directly interacting with RBPJ. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4792-4801.	7.1	16
64	Natural products, PGC-1 , and Duchenne muscular dystrophy. Acta Pharmaceutica Sinica B, 2020, 10, 734-745.	12.0	48
65	The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease. ACS Pharmacology and Translational Science, 2020, 3, 457-471.	4.9	27
66	Epigenetics in atherosclerosis: key features and therapeutic implications. Expert Opinion on Therapeutic Targets, 2020, 24, 719-721.	3.4	4
67	SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity. Aging, 2020, 12, 4178-4192.	3.1	22
68	New trends in the pharmacological intervention of PPARs in obesity: Role of natural and synthetic compounds_. Current Medicinal Chemistry, 2020, 28, 4004-4022.	2.4	2
69	Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation. Journal of Cell Communication and Signaling, 2019, 13, 539-548.	3.4	17
70	MicroRNA targeting by quercetin in cancer treatment and chemoprotection. Pharmacological Research, 2019, 147, 104346.	7.1	68
71	Tollâ€like receptors as novel therapeutic targets for herpes simplex virus infection. Reviews in Medical Virology, 2019, 29, e2048.	8.3	18
72	Letter by Xu Regarding Article, â€œShear-Induced CCN1 Promotes Atheroprone Endothelial Phenotypes and Atherosclerosisâ€• Circulation, 2019, 140, e766-e767.	1.6	0

#	Article	IF	Citations
73	Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease. , 2019, 204, 107404.		38
74	Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products. Pharmacological Reviews, 2019, 71, 596-670.	16.0	118
75	Phosphodiesterase inhibitors say NO to Alzheimer's disease. Food and Chemical Toxicology, 2019, 134, 110822.	3.6	52
76	Targeting BDNF signaling by natural products: Novel synaptic repair therapeutics for neurodegeneration and behavior disorders. Pharmacological Research, 2019, 148, 104458.	7.1	47
77	Iron and Atherosclerosis: The Link Revisited. Trends in Molecular Medicine, 2019, 25, 659-661.	6.7	43
78	The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis. European Heart Journal, 2019, 40, 2398-2408.	2.2	60
79	Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacological Research, 2019, 147, 104307.	7.1	74
80	Myofibroblast-specific YY1 promotes liver fibrosis. Biochemical and Biophysical Research Communications, 2019, 514, 913-918.	2.1	8
81	Bioactive peptides and proteins as alternative antiplatelet drugs. Medicinal Research Reviews, 2019, 39, 2153-2171.	10.5	19
82	Hutchinsonâ€“Gilford Progeria Syndrome: Cardiovascular Pathologies and Potential Therapies. Trends in Biochemical Sciences, 2019, 44, 561-564.	7.5	12
83	Targeting Mechanosensitive Transcription Factors in Atherosclerosis. Trends in Pharmacological Sciences, 2019, 40, 253-266.	8.7	123
84	Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics, 2019, 9, 1923-1951.	10.0	232
85	Trends of tea in cardiovascular health and disease: A critical review. Trends in Food Science and Technology, 2019, 88, 385-396.	15.1	53
86	A simple protocol for isolating mouse lung endothelial cells. Scientific Reports, 2019, 9, 1458.	3.3	40
87	KLHL3 single-nucleotide polymorphism is associated with essential hypertension in Chinese Han population. Medicine (United States), 2019, 98, e15766.	1.0	0
88	SENCRstabilizes vascular endothelial cell adherens junctions through interaction with CKAP4. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 546-555.	7.1	88
89	Targeting STATs in neuroinflammation: The road less traveled!. Pharmacological Research, 2019, 141, 73-84.	7.1	26
90	Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential. Pharmacological Research, 2019, 139, 62-75.	7.1	85

#	Article	IF	Citations
91	Application of the in vivo Pig-a gene mutation assay to test the potential genotoxicity of p-phenylenediamine. Food and Chemical Toxicology, 2019, 123, 424-430.	3.6	6
92	Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. , 2019, 196, 15-43.		110
93	Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu). Pharmacological Research, 2019, 141, 541-550.	7.1	108
94	The berries on the top. Journal of Berry Research, 2019, 9, 125-139.	1.4	23
95	Targeting LOXâ€1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Annals of the New York Academy of Sciences, 2019, 1443, 34-53.	3.8	67
96	GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species. Vascular Biology (Bristol, England), 2019, 1, R1-R11.	3.2	13
97	Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis. , 2018, 187, 88-97.		26
98	Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta Pharmacologica Sinica, 2018, 39, 802-824.	6.1	295
99	A novel SIRT1 activator E6155 improves insulin sensitivity in type 2 diabetic KKAy mice. Biochemical and Biophysical Research Communications, 2018, 498, 633-639.	2.1	12
100	Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen. Medicinal Research Reviews, 2018, 38, 201-228.	10.5	90
101	Tanshinone IIA attenuates TNF-Î± induced PTX3 expression and monocyte adhesion to endothelial cells through the p38/NF-ÎºB pathway. Food and Chemical Toxicology, 2018, 121, 622-630.	3.6	19
102	Hydrogen Sulfide (H2S)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases. Frontiers in Pharmacology, 2018, 9, 1066.	3.5	71
103	Endothelial function and dysfunction: Impact of metformin. , 2018, 192, 150-162.		82
104	Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?. Pharmacological Research, 2018, 135, 37-48.	7.1	24
105	Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics, 2018, 8, 3007-3021.	10.0	51
106	Atherosclerosis Is an Epigenetic Disease. Trends in Endocrinology and Metabolism, 2018, 29, 739-742.	7.1	113
107	Increased expression of DRAM1 confers myocardial protection against ischemia via restoring autophagy flux. Journal of Molecular and Cellular Cardiology, 2018, 124, 70-82.	1.9	25
108	Loss of LMOD1 impairs smooth muscle cytocontractility and causes megacystis microcolon intestinal hypoperistalsis syndrome in humans and mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2739-E2747.	7.1	97

#	Article	IF	Citations
109	Tannic acid as a plant-derived polyphenol exerts vasoprotection via enhancing KLF2 expression in endothelial cells. Scientific Reports, 2017, 7, 6686.	3.3	50
110	Suberanilohydroxamic Acid as a Pharmacological Kruppelâ€Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis. Journal of the American Heart Association, 2017, 6, .	3.7	49
111	Transcriptome Profiling in Systems Vascular Medicine. Frontiers in Pharmacology, 2017, 8, 563.	3.5	22
112	A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. Oncotarget, 2016, 7, 37622-37635.	1.8	63
113	SIRT6 protects against endothelial dysfunction and atherosclerosis in mice. Aging, 2016, 8, 1064-1082.	3.1	88
114	Sirtuins in Cardiovascular Health and Diseases. Trends in Endocrinology and Metabolism, 2016, 27, 677-678.	7.1	21
115	Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells. Translational Research, 2016, 176, 18-28.e2.	5.0	61
116	PECAM1 regulates flow-mediated Gab1 tyrosine phosphorylation and signaling. Cellular Signalling, 2016, 28, 117-124.	3.6	26
117	Enhanced enteroviral infectivityviaviral proteaseâ€mediated cleavage of Grb2â€associated binder 1. FASEB Journal, 2015, 29, 4523-4531.	0.5	19
118	Cryptotanshinone, an orally bioactive herbal compound from <scp>D</scp>anshen, attenuates atherosclerosis in apolipoprotein <scp>E</scp>â€deficient mice: role of lectinâ€like oxidized LDL receptorâ€1 (<scp>LOX</scp>â€1). British Journal of Pharmacology, 2015, 172, 5661-5675.	5.4	61
119	Osthole, a Natural Coumarin Improves Cognitive Impairments and BBB Dysfunction After Transient Global Brain Ischemia in C57 BL/6J Mice: Involvement of Nrf2 Pathway. Neurochemical Research, 2015, 40, 186-194.	3.3	43
120	Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor ÎºB signaling. Translational Research, 2015, 165, 374-386.	5.0	60
121	Essential roles of Gab1 tyrosine phosphorylation in growth factor-mediated signaling and angiogenesis. International Journal of Cardiology, 2015, 181, 180-184.	1.7	34
122	Histone deacetylase 5 interacts with KrÃ¼ppel-like factor 2 and inhibits its transcriptional activity in endothelium. Cardiovascular Research, 2014, 104, 127-137.	3.8	37
123	Poly(ADPâ€ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications. Medicinal Research Reviews, 2014, 34, 644-675.	10.5	77
124	Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. Journal of Lipid Research, 2014, 55, 201-213.	4.2	77
125	Cryptotanshinone Attenuates Cardiac Fibrosis via Downregulation of COX-2, NOX-2, and NOX-4. Journal of Cardiovascular Pharmacology, 2014, 64, 28-37.	1.9	40
126	Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis. International Journal of Cardiology, 2014, 172, 313-317.	1.7	72

#	Article	IF	Citations
127	Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis. International Journal of Cardiology, 2014, 174, 878-880.	1.7	15
128	EEN regulates the proliferation and survival of multiple myeloma cells by potentiating IGF-1 secretion. Biochemical and Biophysical Research Communications, 2014, 447, 271-277.	2.1	9
129	Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling. Archives of Biochemistry and Biophysics, 2014, 562, 22-30.	3.0	12
130	Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in Patients With Lymphangioleiomyomatosis. Chest, 2014, 145, 108-112.	0.8	39
131	Transforming growth factor-Î² signalling: Role and consequences of Smad linker region phosphorylation. Cellular Signalling, 2013, 25, 2017-2024.	3.6	216
132	Tanshinone II-A: new perspectives for old remedies. Expert Opinion on Therapeutic Patents, 2013, 23, 149-153.	5.0	122
133	HDL cholesterol in cardiovascular diseases: The good, the bad, and the ugly?. International Journal of Cardiology, 2013, 168, 3157-3159.	1.7	22
134	Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-Î± partly via preventing p65-NFÎºB binding to NFATc4. Molecular and Cellular Endocrinology, 2013, 370, 103-112.	3.2	42
135	LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cellular and Molecular Life Sciences, 2013, 70, 2859-2872.	5.4	229
136	BIG1, a Brefeldin Aâ€“Inhibited Guanine Nucleotide-Exchange Protein Modulates ATP-Binding Cassette Transporter A-1 Trafficking and Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, e31-8.	2.4	19
137	Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis, 2012, 220, 3-10.	0.8	295
138	Corrigendum to: Cardiovascular actions and therapeutic potential of tanshinone IIA [Atherosclerosis 220 (2012) 3â€“10]. Atherosclerosis, 2012, 221, 604.	0.8	5
139	Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-ÎºB activation. Translational Research, 2012, 160, 114-124.	5.0	78
140	PPARÎ± activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4. Archives of Biochemistry and Biophysics, 2012, 518, 71-78.	3.0	28
141	Roles of transcriptional corepressor RIP140 and coactivator PGC-1Î± in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes. Molecular and Cellular Endocrinology, 2012, 362, 11-18.	3.2	48
142	Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in Apolipoprotein-E knockout mice fed a high cholesterol diet. Archives of Biochemistry and Biophysics, 2011, 515, 72-79.	3.0	76
143	Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: Involvement of NF-ÎºB signaling pathway. Molecular and Cellular Endocrinology, 2011, 331, 34-40.	3.2	129
144	Tanshinone IIA attenuates atherosclerosis in ApoEâ^'/â^' mice through down-regulation of scavenger receptor expression. European Journal of Pharmacology, 2011, 650, 275-284.	3.5	74

#	Article	IF	Citations
145	Osthole, a natural coumarin, improves neurobehavioral functions and reduces infarct volume and matrix metalloproteinase-9 activity after transient focal cerebral ischemia in rats. Brain Research, 2011, 1385, 275-280.	2.2	37
146	Cryptotanshinone Suppressed Inflammatory Cytokines Secretion in RAW264.7 Macrophages through Inhibition of the NF-Î¹B and MAPK Signaling Pathways. Inflammation, 2011, 34, 111-118.	3.8	109
147	Simultaneous determination of sphingosine and sphingosine 1-phosphate in biological samples by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 520-526.	2.3	35
148	Sphingosine Kinase-1 Pathway Mediates High Glucose-Induced Fibronectin Expression in Glomerular Mesangial Cells. Molecular Endocrinology, 2011, 25, 2094-2105.	3.7	60
149	Icariin Derivative Inhibits Inflammation through Suppression of p38 Mitogen-Activated Protein Kinase and Nuclear Factor-.KAPPA.B Pathways. Biological and Pharmaceutical Bulletin, 2010, 33, 1307-1313.	1.4	54
150	Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake. Cytotechnology, 2010, 62, 473-481.	1.6	165
151	Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine, 2010, 18, 58-64.	5.3	36
152	Determination of sphingosine kinase activity in biological samples by liquid chromatographyâ€“tandem mass spectrometry. Biomedical Chromatography, 2010, 24, 1075-1083.	1.7	12
153	Regulated expression of endothelial lipase in atherosclerosis. Molecular and Cellular Endocrinology, 2010, 315, 233-238.	3.2	25
154	Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas. Cytotechnology, 2009, 61, 65-72.	1.6	33
155	Alterations in mRNA expression of BACE1, cathepsin B, and glutaminyl cyclase in mice ischemic brain. NeuroReport, 2009, 20, 1456-1460.	1.2	18
156	Endothelial Cells as a Key Cell Type for Innate Immunity: A Focused Review on RIG-I Signaling Pathway. Frontiers in Immunology, 0, 13, .	4.8	15